Literature DB >> 31111234

Organometallic rhenium tricarbonyl-enrofloxacin and -levofloxacin complexes: synthesis, albumin-binding, DNA-interaction and cell viability studies.

Chaido-Christina Pagoni1, Vasiliki-Styliani Xylouri1,2, Georgios C Kaiafas2, Marialena Lazou3, Georgia Bompola1, Evangelos Tsoukas2, Lefkothea C Papadopoulou2, George Psomas3, Dionysia Papagiannopoulou4.   

Abstract

Organometallic rhenium complexes have recently been considered in the development of novel antitumor agents due to their suitable properties. A series of rhenium(I) tricarbonyl complexes was synthesized with the quinolone antimicrobial agents enrofloxacin (Herx) and levofloxacin (Hlfx) and solvent (e.g., methanol), imidazole (im) or pyridine (py) as co-ligands. The complexes were characterized by spectroscopic methods. The interaction of the rhenium complexes with bovine serum albumin was investigated by fluorescence emission spectroscopy and the corresponding binding constants were determined. The binding of the rhenium complexes to calf-thymus DNA was monitored by UV-Vis spectroscopy, viscosity measurements and competitive studies with ethidium bromide. These studies indicated that intercalation is the most possible mode of action and the corresponding DNA-binding constants of the complexes were calculated. The cytotoxicity of the Re-complexes against human K-562 erythroleukemia cells was found to be moderate to high. These preliminary results are promising and warrant the design of new Re-complexes with improved properties in future studies.

Entities:  

Keywords:  Cytotoxicity; DNA-binding; Enrofloxacin; Levofloxacin; Rhenium complexes

Mesh:

Substances:

Year:  2019        PMID: 31111234     DOI: 10.1007/s00775-019-01666-1

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  51 in total

1.  The status of platinum anticancer drugs in the clinic and in clinical trials.

Authors:  Nial J Wheate; Shonagh Walker; Gemma E Craig; Rabbab Oun
Journal:  Dalton Trans       Date:  2010-06-30       Impact factor: 4.390

Review 2.  Multimodal radio- (PET/SPECT) and fluorescence imaging agents based on metallo-radioisotopes: current applications and prospects for development of new agents.

Authors:  Flora L Thorp-Greenwood; Michael P Coogan
Journal:  Dalton Trans       Date:  2011-01-12       Impact factor: 4.390

Review 3.  Radiometals for combined imaging and therapy.

Authors:  Cathy S Cutler; Heather M Hennkens; Nebiat Sisay; Sandrine Huclier-Markai; Silvia S Jurisson
Journal:  Chem Rev       Date:  2012-11-30       Impact factor: 60.622

4.  Syntheses of bifunctional 2,3-diamino propionic acid-based chelators as small and strong tripod ligands for the labelling of biomolecules with (99m)Tc.

Authors:  Yu Liu; Bruno L Oliveira; João D G Correia; Isabel C Santos; Isabel Santos; Bernhard Spingler; Roger Alberto
Journal:  Org Biomol Chem       Date:  2010-05-06       Impact factor: 3.876

5.  Uptake and localisation of rhenium fac-tricarbonyl polypyridyls in fluorescent cell imaging experiments.

Authors:  Vanesa Fernández-Moreira; Flora L Thorp-Greenwood; Angelo J Amoroso; Joanne Cable; Jonathan B Court; Victoria Gray; Anthony J Hayes; Robert L Jenkins; Benson M Kariuki; David Lloyd; Coralie O Millet; Catrin Ff Williams; Michael P Coogan
Journal:  Org Biomol Chem       Date:  2010-06-30       Impact factor: 3.876

Review 6.  Underestimated potential of organometallic rhenium complexes as anticancer agents.

Authors:  Anna Leonidova; Gilles Gasser
Journal:  ACS Chem Biol       Date:  2014-08-25       Impact factor: 5.100

Review 7.  Role of tyrosine kinase inhibitors in cancer therapy.

Authors:  Amit Arora; Eric M Scholar
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

8.  Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.

Authors:  R Krishna; L D Mayer
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

9.  Potential mechanisms of resistance to venetoclax and strategies to circumvent it.

Authors:  Stephen K Tahir; Morey L Smith; Paul Hessler; Lisa Roberts Rapp; Kenneth B Idler; Chang H Park; Joel D Leverson; Lloyd T Lam
Journal:  BMC Cancer       Date:  2017-06-02       Impact factor: 4.430

10.  An overview of targeted cancer therapy.

Authors:  Viswanadha Vijaya Padma
Journal:  Biomedicine (Taipei)       Date:  2015-11-28
View more
  2 in total

Review 1.  Target-specific mononuclear and binuclear rhenium(i) tricarbonyl complexes as upcoming anticancer drugs.

Authors:  Ajay Sharma S; Vaibhavi N; Binoy Kar; Utpal Das; Priyankar Paira
Journal:  RSC Adv       Date:  2022-07-14       Impact factor: 4.036

Review 2.  Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives.

Authors:  Kevin Schindler; Fabio Zobi
Journal:  Molecules       Date:  2022-01-15       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.